[go: up one dir, main page]

WO1999050424A2 - Preparation et utilisation d'antigenes - Google Patents

Preparation et utilisation d'antigenes Download PDF

Info

Publication number
WO1999050424A2
WO1999050424A2 PCT/GB1999/000978 GB9900978W WO9950424A2 WO 1999050424 A2 WO1999050424 A2 WO 1999050424A2 GB 9900978 W GB9900978 W GB 9900978W WO 9950424 A2 WO9950424 A2 WO 9950424A2
Authority
WO
WIPO (PCT)
Prior art keywords
sequence
protein
virus
terminal
vlps
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB1999/000978
Other languages
English (en)
Other versions
WO1999050424A3 (fr
Inventor
Margaret Anne Stanley
Wei Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to AU31594/99A priority Critical patent/AU3159499A/en
Priority to EP99913478A priority patent/EP1066391A2/fr
Publication of WO1999050424A2 publication Critical patent/WO1999050424A2/fr
Publication of WO1999050424A3 publication Critical patent/WO1999050424A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]

Definitions

  • This invention relates to antigen preparation and use, for example to antigen preparations comprising modified virus-like particles of papovaviruses, e.g. of papillomaviruses.
  • the invention also relates to the production and purification of such antigen preparations, and to corresponding recombinant-nucleic acid constructs e.g. expression cassettes, plasmids, recombinant cells and recombinant viruses applicable to such production.
  • the invention further relates to the use of such antigenic preparations in the production of immune responses, and to vaccines based on such preparations. Background of the invention
  • Papillomaviruses are members of the papovavirus class of viruses and human papillomaviruses (HPV) in particular are known as agents of disease.
  • HPV human papillomaviruses
  • infection with HPV type 6 is associated with condyloma acuminatum (genital warts) and HPV type 16 is believed to be a major risk factor for the development of cervical carcinoma.
  • papillomavirus proteins and derivatives of them have been used or proposed for use in vaccines in relation to diseases associated with papillomaviruses.
  • the DNA sequences of many of the papillomavirus proteins themselves are well-known: see for example the series 'Human Papillomaviruses', eds. G Myers et al, published annually at Los Alamos, New Mexico, USA, by Los Alamos National Laboratory (Theoretical Biology and Biophysics, group T10, mailstop K710). See for example references given in issues for 1994 and 1995.
  • Heterologous expression of papillomavirus proteins is also per-sewell known, using conventional cloning technique. References for example can be found in the issues of Human Papillomaviruses (see above) for 1994 and 1995.
  • Proteins of many papillomavirus types are known, either directly as proteins, or indirectly by viral DNA sequences that encode them, and some have been expressed by recombinant DNA technique in heterologous expression systems.
  • VLPs virus-like particles
  • VLPs have been shown to possess immunogenic conformational epitopes not evident in denatured forms of the corresponding viral proteins.
  • virus-like particles comprise the major coat protein L1 in the case of papillomaviruses, and can optionally also comprise the minor coat protein L2.
  • Fusion proteins have also been made on the basis of papillomavirus L1 protein. For example, fusion proteins have been reported comprising HPV16 E7 peptides fused to the C-terminus of L1 , the major capsid protein of HPV16, and these have been previously shown to assemble into chimeric virus-like particles (CVLPs). These E7 peptides have been reported as being internally located in the VLPs (Muller et al., Virology 234, 93-111 , 1997).
  • the invention rpovides inter alia a fusion protein comprising a sequence from a major coat protein of a papovavirus, in which the N-terminal of the sequence derived from the major coat protein is fused to a further peptide sequence. Also provided by the invention is a virus-like particle comprising such a fusion protein.
  • modified major coat proteins of papovaviruses in which the N-terminal of the major coat protein is fused to a further peptide sequence, can be produced by recombinant DNA. technique.
  • resulting virus-like particles which can be described as chimeric VLPs
  • such further peptides can be displayed in such a way that they are immunogenic.
  • the displayed peptides can also have sequences that provide specific domains for the (affinity) purification of the VLPs.
  • the resulting modified VLPs can also retain conformational epitopes of the corresponding VLPs based on unmodified coat protein(s). Products of the invention can be useful as antigens.
  • Papovavirus protein involved in such chimeric VLPs can be for example a papillomavirus protein, e.g. human papillomavirus L1 protein from HPV of type 16 or 18.
  • other papillomavirus L1 protein sequences can be used as the basis of the modified proteins, e.g. human papillomavirus L1 of other HPV types such as for example types 1 ,2, 6 or 11 , or 35 or 45, to name several examples that can be useful sources of immunogens related to human papillomavirus infections against which immunogens and vaccines are desired.
  • Major coat proteins of other papovaviruses can be used as the basis of modification if desired, e.g. the major coat protein of SV40 virus.
  • HPV L1 fusion protein with an N-terminal sequence extension has been expressed in the per-se known baculovirus system in the form of VLPs, i.e. modified VLPs.
  • This kind of fusion protein comprises, e.g. in an example described below, L1 protein and fused to its N-terminal a sub-sequence from a further protein, for example a papillomavirus early protein such as HPV E1 or E2, E6 or E7.
  • the sub- sequence is preferably long enough to provide at least one epitope of the further protein, e.g. about 15 residues, such as for example residues 45-60 of the E1 aa sequence, alternatively or additionally residues 384-403 of the E1 aa sequence.
  • the E1 aa 45-60 sequence and the 384-403 sequence are believed to be targets of a dominant antibody response obtainable on immunising mice with full-sequence E1 protein.
  • fusion protein can be an L1 protein fused at its N-terminal to a short peptide sequence e.g. of about 6-20 aminoacids, e.g. a his-tag or an epitope recognisable by an antibody.
  • VLPs displaying his-tags can be purified after CVLP assembly, e.g. on an appropriate resin such as nickel-NTA-agarose (Qiagen) or Talon-metal affinity resin (Clontech).
  • Epitopes can provide the basis for affinity purification e.g. on an antibody-conjugated protein-G or protein-A derivatised resin.
  • the C-terminal of) the chosen peptide sequence can be fused on to the N- terminal of the L1 sequence. This is achieved by construction of a corresponding encoding polynucleotide and its incorporation into an expression vector and subsequence expression by per-se wellknown rDNA methods, e.g. in the baculovirus system as in the example given below.
  • VLP preparation based on such a fusion protein has been shown to have the following properties: - it is recognised by an antibody from the immune response against the full- sequence protein of which a sub-sequence was fused to the N-terminal of the L1 protein;
  • the invention also provides modified VLPs that (a) retain the native conformation of the structure of the corresponding VLPs based on major coat protein of corresponding unmodified sequence while also (b) presenting to the immune system of a subject immunised with the modified VLPs an epitope present on the N-terminal extension of the major coat protein sequence.
  • the modified major coat protein can have further features and modifications for example as follows:
  • the N-terminal extension of the major coat protein sequence can comprise a heterologous protein sub-sequence eg it can comprise the sequence of an epitope that is recognisable by a B-cell, e.g. either a neutralising or a non-neutralising epitope, or an epitope that is recognisable by a T-cell, or more than one epitope of either kind or more than one kind.
  • a heterologous protein sub-sequence eg it can comprise the sequence of an epitope that is recognisable by a B-cell, e.g. either a neutralising or a non-neutralising epitope, or an epitope that is recognisable by a T-cell, or more than one epitope of either kind or more than one kind.
  • Heterologous' in this context means having a sequence other than that which is native to the unmodified N-terminal of the wild-type papovavirus major coat protein most nearly corresponding to the structural protein of the modified (chimeric) VLP preparation according to the example of the invention that is under consideration.
  • the N-terminal extension can be for example of at least about 10 aminoacids in length and up to about 15 aminoacids in length; it can also be somewhat longer, e.g. up to 30, 40, 50 or sometimes 60 aminoacids in length, or as desired, with the proviso that the extension sequence should not be so long that it disrupts the formation of the VLP structure. This can be judged if desired or if need be by per-se known methods, e.g. by comparative electron-microscopic examination of a preparation of the modified protein made under conditions that correspond to VLP- forming conditions in the case of a coat protein that is similar except that it has a shorter or zero-length N-terminal aminoacid sequence extension.
  • the normal sequence at the N-terminal of the major coat protein L1 to which a heterologous epitope is added as described herein can also if desired be truncated. Such truncation can be chosen so as not to disrupt the ability of the resulting mutant L1 protein with N-terminal sequence extension to form VLPs. For example, deletion of up to about 10 aminoacids of the N-terminal L1 can result in enhanced formation of VLPs in baculovirus-infected insect cells. The ability of mutant L1 proteins with N-terminal sequence extension to form VLPs can be tested when desired e.g. by the electron-microscopic technique described by way of example below.
  • N-terminal extension aminoacid sequence can be chosen e.g. from among the following:
  • HIV envelope glycoprotein gp120 e.g. a sub-sequence from the region aa384 to aa467 of gp120, (as identified by PNAS 85: (1988) 7957-7961, J Virol 64: 2452-2455 and/or referenes cited therein), which sequence has been reported as giving rise to both humoral (antibody) and T-cell proliferative response to HIV protein gp120; — a sub-sequence of HIV envelope glycoprotein gp120, from the region aa428 to aa443 of gp120, (env Ti as identified in Nature 334: 706-708 as a T-cell epitope);
  • T-cell- and B-cell-recognised epitopes such as a poliovirus T-cell epitope as described in J Virol 65 (1991 ) 711-718 (from positions 103-115 of poliovirus VP1 capsid protein); or a B-cell neutralising epitope from human poliovirus VP1 protein positions aa93-103, as described in Science 233 1986 472-475; or a rhinovirus neutralising epitope from positions aa153-164 of VP2 protein of HRV2 as described in J Gen Virol 68 1987315-323 and 2687-2691 ; or an epitope from herpes simplex virus/parvovirus (hybrid neutralising epitope from gD envelope protein), as described in J Virol 49 1984 102-108 or Virology 198 1994477-480; or a HIV 38-aa neutralising domain sequence from within the V3 loop of gp120, as described in PNAS 86 1989 6768-6772;
  • the invention also provides a method of inducing an immune response to a T-cell-recognised epitope or a B-cell-recognised epitope, which comprises immunising a subject to be treated with a preparation of modified papovavirus VLPs in which the major coat protein component has an aminoacid sequence wherein the T-cell epitope or B-cell epitope sequence against which the immune response is to be generated is present in a N-terminal sequence extension of said major coat protein component.
  • VLP preparations according to the invention including pharmaceutical formulations e.g. in sterile injectable dosage forms comprising the VLPs along with e.g. per-se known excipients, are expected to provide useful prophylactic and therapeutic immune responses related to epitopes present on the N-terminal aminoacid sequence extensions described above.
  • Figure 1 A is a plasmid diagram showing constructs for expressing L1 protein of HPV with fused N-terminal peptides, suitable for making protein preparations according to embodiments of the invention.
  • Figure 1 B is a plasmid diagram showing constructs for expressing L1 protein of HPV full-length and with N-terminal or C-terminal deletions.
  • Figures 2A, 2B and 2C show electron micrographs of particles formed from one of the protein fusions corresponding to Figure 1 A.
  • Figures 3A and 3B show electron micrographs of particles formed from another of the protein fusions corresponding to Figure 1 A.
  • Figures 4A, 4B and 4C show Western blots diagnostic of the presence of fusion peptides in protein fusions expressed from the constructs of Figure 1A.
  • Figure 5 shows a Western blot indicative of expression of N-terminal truncated proteins corresponding to Figure 1 B.
  • Figure 6 shows an electron micrograph of VLPs formed from one of the N- terminal truncated proteins corresponding to Figure 1B.
  • Figure 7 shows ELISA testing of fractions from expression of N-terminal truncated L1 proteins corresponding to Figure 1B.
  • Figure 8 shows results of density gradient centhfugation of particles formed by one of the N-terminal truncated L1 proteins corresponding to Figure 1B.
  • Figure 9 shows ELISA testing of fractions from expression of aminoacid substitution mutants of L1 protein.
  • Fusion proteins comprising HPV16 E7 peptides fused to the C-terminus of L1 protein were previously shown to assemble into chimeric virus-like particles.
  • the present example describes fusion of epitopes recognised by respective monoclonal antibodies at the N-terminus of L1 protein and expression of the corresponding hybrid protein in a baculovirus system. Fusion proteins as indicated below were able to self-assemble into chimeric VLPs and fused epitope was found to be presented on the sur ace of such VLPs, without interfering with the reactivity of the conformation-dependent neutralising epitopes.
  • the N-terminus of the L1 protein is shown to be suitable for epitope fusion and presentation.
  • Chimeric VLPs generated in this and analogous ways can be used for immunisation against dual or multiple epitopes.
  • HPV16 L1 ORF For generation of recombinant (A), the sequence of HPV16 L1 ORF was amplified by polymerase chain reaction (PCR) from a total DNA extract of W12, an HPV16 episome-containing cell line (Stanley M, Brown HM, Appleby M, and Minson AC (1989) "Properties of a non-tumorigenic human keratinocyte cell line", Int J Cancer 43, 672-676) using a forward primer in which a Bgl II restriction sequence was included (underlined) 5'-GCT GCA AGA TCT ATG TCT CTT TGG CTG CCT AG-3'.
  • PCR polymerase chain reaction
  • a DNA nucleotide sequence encoding the E1 50-65 sequence plus a Bgl II restriction sequence was introduced just in front of the L1 coding sequence as a forward primer, as follows:
  • a nucleotide sequence encoding E1 amino acids 384-403 was introduced just in front of E1 50-65 coding sequence of the last-mentioned construct, using a forward primer with a flanking Bgl II restrictional sequence (underlined): 5 '-GCT GCA AGA TCT ATG TAC GAT AAT GAC ATA GTA GAC GAT AGT GAA ATT GCA TAT AAA TAT GCA CAA TTG GCA GAC GTA GAT TTT ATA GTA AAT GAT-3'.
  • the DNA products (e.g. of about 1.7kb in size) were gel purified, GENECLEAN (TM) excised, digested with restriction enzymes of Bgl II and Not I and sub-cloned into baculovirus transfer vector pBacAK ⁇ (Clontech) which had been pre-digested with BamHI and Notl restriction enzymes.
  • the recombinant plasmids for cases (A), (B) and (C) were examined by sequencing in per-se known manner (Pharmacia (TM) kit). Generation of recombinant baculoviruses:
  • Insect cells of Spodoptera frugiperda were grown in 30 mm dishes until 80% confluent, at 27°C with TNMFH medium (Sigma) supplemented with 10% foetal calf serum.
  • TNMFH medium Sigma
  • 0.5 micro-g DNA of each respective transfer recombinant together with 5 micro-l of Bsu36 I digested pBacPAK ⁇ viral genomic DNA (Clontech) were co- transfected into the insect cells by following the instruction of the supplier.
  • All the agents were applied but viral genomic DNA.
  • Recombinant viruses were plaque purified by per-se known technique and further expanded by multiple cycles of cell infection.
  • sf21 cells were infected with each of the baculovirus recombinants e.g. at MOI about 5-10. After 72 hrs of infection, cells were harvested, lysed, analysed by SDS-PAGE and immunoblotting with one of the following monoclonal antibodies (mAbs), i.e. anti-L1 mAb Camvir 1 (McLean CS, Churcher MJ, Smith GL, Higgins G, Stanley M, and Minson AC (1990) in "Production and characterisation of a monoclonal antibody to human papillomavirus type 16 using recombinant vaccinia virus" J Clin. Pathol.
  • mAbs monoclonal antibodies
  • an anti-E1 50-65 amino acid mAb designated alpha-E1n or an anti-E1 384-403 amino acid mAb alpha-E1 m was expressed by a hybridoma produced by immunising mice with full-length E1 protein of HPV expressed in a standard E coli host expression system, and selecting hybridomas with the ability to produce antibody of the desired specificity using tre 50-65 or the 384-403 peptide of E1 protein in per-se known manner. Purification of virus-like particles:
  • the cells were harvested by cent fugation and each of the cell pellets (containing about 1 x 10 ⁇ 8 cells) was resuspended into 15 ml of PBS and homogenised with 50-100 strokes with a Dounce homogenizer (BDH). Nuclei were separated by centhfugation at 2000 x g for 20 min and the pellet was resuspended in 4 ml of PBS and mildly sonicated for 30 seconds at mark 18 (Branson Sonifier (TM)) on ice. The nuclei lysate was layered onto a 0.75 ml of 40% (w/v) sucrose-PBS cushion and centrifuged at 34,000 rpm for 2 hours in a Beckman SW55Ti rotor.
  • BDH Dounce homogenizer
  • the suspension was centrifuged at 45,000 rpm for 16 hours in a SW55 Ti rotor at 18 deg C. After centrifugation, double-bands of the particles, either VLP's or chimeric VLPs corresponding to fusion proteins (B) or (C), in the middle of the centrifuge tube, were collected by puncturing the tube with a needle.
  • the densities of the collected bands were examined with refractometer (Bellingham & Stanley Ltd. England), and were of e.g.
  • the particles with a protein concentration of 100-500 micro-g/ml were spotted onto a glow- discharged carbon coated grid and negative stained with 2% phosphotungstic acid solution (pH 6.8) and viewed with a Phillips CM 100 transmission electron microscope.
  • immuno-gold labelling was applied as follows.
  • the grids with the particles were stained with an antibody, either alpha-E1n, or alpha- Elm, or H16.V5 (an HPV16 neutralising mAb specifically recognising the conformational epitope of the virion, as described by NC Christensen, J Dillner, C Eklund, JJ Carter, CA Reed, NM Cladel, and DA Galloway (1995): 'Surface conformational and linear epitopes on HPV16 and HPV18 virus-like particles as defined by monoclonal antibodies': Virology 223 (1995) 174-184).
  • the antibodies were all diluted 1 : 50 in 5% milk PBST blocking buffer, and incubated at room temperature for 1 hour.
  • mice were then washed with 1 % milk/PBST 3 times at 5 mm for each interval.
  • the grids were then stained with 10 nm gold conjugated anti- mouse IgG (Sigma) at room temperature for 1 hour, then subjected to 3 washes with 1 % milk/PBST and 3 washes with distilled water.
  • the grids were then stained with 2% (w/v) phosphotungstic acid pH 6.8) and viewed with a Philips CM 100 (TM) transmission electron microscope.
  • mice Six-week-old BALB/c mice can be used for immunisation e.g. to test for immunogenicity.
  • the preimmune serum can be sampled prior to immunising the mice e.g. with about 5 micro-g purified VLPs or respective chimeric VLPs in phosphate-buffered saline PBS with or without adjuvant per injection subcutaneously at 3 x 2 weeks intervals. Serum samples can be collected 3-4 days after each booster immunisation, heat-inactivated e.g. at 56 deg C for 30 mm, then tested by ELISA.
  • Figure 1A shows a plasmid diagram showing constructs based on commercially available plasmid pBacPAK ⁇ (5.5kb) with insertion of coding sequences for expressing L1 protein of HPV with fused N-terminal peptides as follows, either 15 aminoacids from HPV E1 protein residues 50-64 ('L1-15E1', case B in Example 1 ), or 20 aminoacids from HPV E1 protein residues 384-403 and 15 aminoacids from HPV E1 protein residues 50-64 ('L1-35E1', case C in Example 1 ).
  • These fusion proteins are suitable examples for making chimeric VLP preparations according to embodiments of the invention.
  • Figure 1 B shows plasmid constructs for expressing L1 protein of HPV full- length (starting with base number 5638 and ending with base number 7155 in HPV genome sequence) and with N-terminal deletions of respectively 10, 20 and 30 aminoacid residues (starting with base number 5608, 5578 or 5548 in HPV genome sequence), or C-terminal deletions of respectively 15 and 30 aminoacid residues (ending at base number 7110 or 7065 in HPV genome sequence).
  • Figures 2A, 2B and 2C show electron micrographs of particles formed from protein fusion L1-15E1.
  • Figures 3A and 3B show electron micrographs of particles formed from protein fusion L1-35E1.
  • Figure 3A shows negatively-stained particles
  • Figure 3B shows particles immuno-stained with mAb H16.V5 specific for HPV16 conformational-dependent epitope, indicating chimeric VLP formation.
  • Figures 4A, 4B and 4C show Western blots of L1 protein (as control) and of L1-15E1 and L1-35E1 fusion proteins, using ant-L1 antibody (4A), antibody specific for E1 aa50-64 epitope (4B), and antibody specific for E1 384-403 epitope (4C), indicating presence of appropriate respective fusion peptides in protein fusions expressed from the constructs of Figure 1A.
  • Figure 5 shows a Western blot indicative of expression of the N-terminal truncated proteins corresponding to Figure 1B, showing that each protein was expressed and that the molecular weights declined as expected with the deletions.
  • Figure 6 shows an electron micrograph of VLPs formed from the N-terminal 10-aa truncated L1 protein corresponding to Figure 1B, indicating that this deletion did not affect VLP assembly.
  • the yield of VLPs here was increased compared with yield from wild-type L1.
  • VLPs were not seen in corresponding tests with the 20-aa and 30-aa N-terminal deletions.
  • Figure 7 shows ELISA testing of fractions from expression of L1 protein (control) and each of the N-terminal truncated L1 proteins corresponding to Figure 1 B.
  • the ELISA used a mAb recognising the conformational epitope in VLPs of HPV16 L1.
  • the conformational epitope was detected in preparations from wild-type L1 and the 10-aa N-terminal deletion only. As the amount of protein expressed was approximately the same in each case, loss of detection of comformational epitope was not due to low protein level.
  • Figure 8 shows results of density gradient centhfugation of particles which it was concluded were pentameric structures formed by the 30-aa N-terminal truncated L1 protein corresponding to Figure 1 B, with full-length L1 as control.
  • Total lysates from the expression system were separated on 5-50% sucrose gradients and Western blotting done with anti-L1 antibody.
  • Markers at 11s (catalase) and 19s (beta-galactosidase) indicate pentameric capsomer formation from the 30-aa N- terminal truncated L1 protein (fractions 5-12), whereas fully assembled VLPs are found for full-length L1 protein in fractions 19-25.
  • Figure 9 shows ELISA testing of fractions from expression of aminoacid substitution mutants of L1 protein. Mutagenesis of pro(14)->gly and pro(17)->gly in the full-length L1 sequence resulted in retention of the ability to form VLPs as assessed by reactivity with antibody to the conformational epitope.
  • the invention in several examples provides chimeric VLPs based on protein fusions comprising N-terminal peptides fused to HPV L1 protein of full sequence, or with N-terminal deletion, e.g. of preferably up to about 10 amino-acids, or with aa substitution mutations, especially those that leave the mutant fusion protein still able to form VLPs.
  • N-terminal deletions e.g. of preferably up to about 10 amino-acids, or with aa substitution mutations, especially those that leave the mutant fusion protein still able to form VLPs.
  • C-terminal deletions of the L1 sequence there can be C-terminal deletions of the L1 sequence.
  • N-terminal fusion proteins contained in chimeric VLPs as described herein can retain the native conformation of the corresponding native VLP structure while also presenting to the immune system of a treated immunised subject whatever epitope is present on the N-terminal extension.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Des particules de type viral modifiées (VLP) peuvent comprendre des protéines de fusion comportant une séquence provenant d'une protéine de coque principale d'un papovavirus, par exemple la protéine L1 de HPV 16 ou 18, dans laquelle le N-terminal de la séquence dérivée de la protéine coque principale est fusionné à une nouvelle séquence peptidique. Les VLP peuvent contenir une séquence complète d'une protéine L1 ou une séquence de L1 avec une délétion de N-terminal ou une séquence de L1 avec une mutation de substitution d'acide aminé, et éventuellement une délétion de séquence de L1 de C-terminal. La séquence peptidique fusionnée au N-terminal peut être immunogène, provenant par exemple d'une protéine de pathogène tel qu'un virus. La nouvelle séquence peptidique peut produire un domaine de liaison pour une purification par affinité de la VLP. Des VLP modifiées peuvent maintenir la conformation d'origine de la structure de VLP, tout en présentant également au système immunitaire d'un sujet immunisé avec la VLP modifiée, un épitope présent sur une extension de N-terminal de la séquence de protéine de coque principale. L'invention concerne également des polynucléotides correspondants, des vecteurs d'expression, des plasmides, des vecteurs et des cellules contenant ces polynucléotides.
PCT/GB1999/000978 1998-03-27 1999-03-29 Preparation et utilisation d'antigenes Ceased WO1999050424A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU31594/99A AU3159499A (en) 1998-03-27 1999-03-29 Antigen preparation and use
EP99913478A EP1066391A2 (fr) 1998-03-27 1999-03-29 Preparation et utilisation d'antigenes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9806666.5A GB9806666D0 (en) 1998-03-27 1998-03-27 Antigen preparation and use
GB9806666.5 1998-03-27

Publications (2)

Publication Number Publication Date
WO1999050424A2 true WO1999050424A2 (fr) 1999-10-07
WO1999050424A3 WO1999050424A3 (fr) 1999-12-02

Family

ID=10829441

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1999/000978 Ceased WO1999050424A2 (fr) 1998-03-27 1999-03-29 Preparation et utilisation d'antigenes

Country Status (4)

Country Link
EP (1) EP1066391A2 (fr)
AU (1) AU3159499A (fr)
GB (1) GB9806666D0 (fr)
WO (1) WO1999050424A2 (fr)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001002551A3 (fr) * 1999-06-30 2001-11-08 Evotec Biosystems Ag Particules de type viral, preparation et utilisation de ces dernieres, de preference dans le criblage pharmaceutique et la genomique fonctionnelle
WO2001032851A3 (fr) * 1999-11-03 2002-02-28 Acgt Progenomics Ag Systemes de transport modulaires pour substances moleculaires et fabrication et utilisation de ces systemes
WO2002092796A1 (fr) * 2001-05-15 2002-11-21 Liang Qiao Pseudopapillovirus et son mode de preparation
WO2003078455A3 (fr) * 2002-03-18 2003-12-24 Glaxosmithkline Biolog Sa Vaccin
WO2004052395A1 (fr) * 2002-12-09 2004-06-24 Glaxosmithkline Biologicals Sa Peptide l2 du papillomavirus associe a une particule pseudo-virale
WO2006113209A1 (fr) 2005-04-15 2006-10-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Procedes et compositions permettant de produire une reponse immunitaire amelioree contre un immunogene papillomavirus humain
EP1895018A3 (fr) * 2006-08-28 2008-04-30 Genome Identification Diagnostics GmbH Procédé et moyen de mise en évidence de papillomavirus humains
US7419802B2 (en) 1999-06-30 2008-09-02 Evotec Ag Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics
US7476517B2 (en) 1999-06-30 2009-01-13 Evotec Ag Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics
CZ301144B6 (cs) * 2008-09-15 2009-11-18 Vysoká škola chemicko technologická v Praze Príprava monoklonálních protilátek proti FoxP3 proteinu s použitím modifikovaných virum podobných cástic Masonova-Pfizerova opicího viru
US7641896B2 (en) 2002-07-05 2010-01-05 Folia Biotech Inc. Adjuvant viral particle
US7758866B2 (en) 2004-06-16 2010-07-20 Glaxosmithkline Biologicals, S.A. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
US7815915B2 (en) 2002-03-18 2010-10-19 Glaxosmithkline Biologicals, S.A. Mixture of human papillomavirus virus-like particles
US7858098B2 (en) 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
EP2377879A1 (fr) * 2010-04-14 2011-10-19 Deutsches Krebsforschungszentrum Protéines de fusion HPV E7 à terminaison N
US8101189B2 (en) 2002-07-05 2012-01-24 Folia Biotech Inc. Vaccines and immunopotentiating compositions and methods for making and using them
US8628784B2 (en) 1998-10-16 2014-01-14 Glaxosmithkline Biologicals S.A. Adjuvant systems and vaccines
KR20200027956A (ko) * 2017-06-23 2020-03-13 패쏘백스 엘엘씨 키메라 바이러스-유사 입자 및 면역 반응의 항원-특이적 재지향자로서의 이의 용도
US11560408B2 (en) 2018-12-27 2023-01-24 Verimmune Inc. Conjugated virus-like particles and uses thereof as anti-tumor immune redirectors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE9106105U1 (de) * 1991-05-17 1991-09-26 Behringwerke Ag, 3550 Marburg Diagnose-Kit zum Nachweis von Human-Papillomavirusinfektionen
AUPM358894A0 (en) * 1994-01-31 1994-02-24 Csl Limited Modified papilloma virus l2 protein and vlps formed therefrom
GB9420146D0 (en) * 1994-10-06 1994-11-23 Cancer Res Campaign Tech Papillomavirus vaccine
DE19526752C2 (de) * 1995-07-21 1997-08-07 Lutz Prof Dr Gissmann Hocheffiziente Bildung von Papillomavirusähnlichen Partikeln
ES2264563T3 (es) * 1994-10-07 2007-01-01 Loyola University Of Chicago Particulas semejantes al virus del papiloma, proteinas de fusion y procedimiento para su preparacion.
US6228368B1 (en) * 1997-10-06 2001-05-08 Loyola University Of Chicago Papilloma virus capsomere formulations and method of use

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8628784B2 (en) 1998-10-16 2014-01-14 Glaxosmithkline Biologicals S.A. Adjuvant systems and vaccines
WO2001002551A3 (fr) * 1999-06-30 2001-11-08 Evotec Biosystems Ag Particules de type viral, preparation et utilisation de ces dernieres, de preference dans le criblage pharmaceutique et la genomique fonctionnelle
US7419802B2 (en) 1999-06-30 2008-09-02 Evotec Ag Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics
US7476517B2 (en) 1999-06-30 2009-01-13 Evotec Ag Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics
WO2001032851A3 (fr) * 1999-11-03 2002-02-28 Acgt Progenomics Ag Systemes de transport modulaires pour substances moleculaires et fabrication et utilisation de ces systemes
WO2002092796A1 (fr) * 2001-05-15 2002-11-21 Liang Qiao Pseudopapillovirus et son mode de preparation
US8129144B2 (en) 2001-05-15 2012-03-06 Loyola University Chicago Papilloma pseudovirus and preparation
US7815915B2 (en) 2002-03-18 2010-10-19 Glaxosmithkline Biologicals, S.A. Mixture of human papillomavirus virus-like particles
WO2003078455A3 (fr) * 2002-03-18 2003-12-24 Glaxosmithkline Biolog Sa Vaccin
JP2005538938A (ja) * 2002-03-18 2005-12-22 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
US7205125B2 (en) 2002-03-18 2007-04-17 Glaxosmithkline Biologicals Sa Mixed Virus-like particles
US8282940B2 (en) 2002-07-05 2012-10-09 Folia Biotech Inc. Adjuvant viral particle
US7641896B2 (en) 2002-07-05 2010-01-05 Folia Biotech Inc. Adjuvant viral particle
US9339535B2 (en) 2002-07-05 2016-05-17 Folia Biotech, Inc. Vaccines and immunopotentiating compositions and methods for making and using them
US8101189B2 (en) 2002-07-05 2012-01-24 Folia Biotech Inc. Vaccines and immunopotentiating compositions and methods for making and using them
WO2004052395A1 (fr) * 2002-12-09 2004-06-24 Glaxosmithkline Biologicals Sa Peptide l2 du papillomavirus associe a une particule pseudo-virale
US7858098B2 (en) 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
US7758866B2 (en) 2004-06-16 2010-07-20 Glaxosmithkline Biologicals, S.A. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
US7691579B2 (en) 2005-04-15 2010-04-06 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
WO2006113209A1 (fr) 2005-04-15 2006-10-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Procedes et compositions permettant de produire une reponse immunitaire amelioree contre un immunogene papillomavirus humain
EP1895018A3 (fr) * 2006-08-28 2008-04-30 Genome Identification Diagnostics GmbH Procédé et moyen de mise en évidence de papillomavirus humains
CZ301144B6 (cs) * 2008-09-15 2009-11-18 Vysoká škola chemicko technologická v Praze Príprava monoklonálních protilátek proti FoxP3 proteinu s použitím modifikovaných virum podobných cástic Masonova-Pfizerova opicího viru
WO2011128247A1 (fr) * 2010-04-14 2011-10-20 Deutsches Krebsforschungszentrum Protéines de fusion hpv e7 n-terminales
EP2377879A1 (fr) * 2010-04-14 2011-10-19 Deutsches Krebsforschungszentrum Protéines de fusion HPV E7 à terminaison N
KR20200027956A (ko) * 2017-06-23 2020-03-13 패쏘백스 엘엘씨 키메라 바이러스-유사 입자 및 면역 반응의 항원-특이적 재지향자로서의 이의 용도
JP2020524710A (ja) * 2017-06-23 2020-08-20 パソヴァックス エルエルシー 免疫応答の抗原特異的リダイレクターとしてのキメラウイルス様粒子およびその使用
US11944677B2 (en) 2017-06-23 2024-04-02 Verimmune Inc. Chimeric virus-like particles and uses thereof as antigen-specific redirectors of immune responses
KR102797824B1 (ko) * 2017-06-23 2025-04-17 버이뮨 아이엔씨. 키메라 바이러스-유사 입자 및 면역 반응의 항원-특이적 재지향자로서의 이의 용도
US11560408B2 (en) 2018-12-27 2023-01-24 Verimmune Inc. Conjugated virus-like particles and uses thereof as anti-tumor immune redirectors

Also Published As

Publication number Publication date
GB9806666D0 (en) 1998-05-27
EP1066391A2 (fr) 2001-01-10
AU3159499A (en) 1999-10-18
WO1999050424A3 (fr) 1999-12-02

Similar Documents

Publication Publication Date Title
EP0789766B1 (fr) Particules de type papillomavirus chimeriques
Müller et al. Chimeric papillomavirus-like particles
AU2004203609B2 (en) Self-assembling recombinant papillomavirus capsid proteins
EP1066391A2 (fr) Preparation et utilisation d'antigenes
JP4505452B2 (ja) 酵母におけるｈｐｖ３１ｌ１の最適化発現
NO328128B1 (no) Antigenisk formulering som omfatter et humant papillomaviruskapsomer for anvendelse som en vaksine, samt anvendelse derav for fremstilling av en farmasoytisk sammensetning for behandling og forebygging av HPV infeksjon og tilstander beslektet dermed.
EP1305039B1 (fr) Formes (fixes) stables de proteines l1 virales capsidiales et de proteines virales capsidiales hybrides et leurs utilisations
WO2012031760A1 (fr) Protéines structurales mutées de parvovirus comprenant des épitopes de cellules b induisant une protection croisée d'une protéine l2 du hpv ainsi que produits et procédés s'y rapportant
US7691386B2 (en) Chimeric papillomavirus-like particles
US20020193565A1 (en) Antigen preparation and use
Kuck et al. Efficiency of HPV 16 L1/E7 DNA immunization: influence of cellular localization and capsid assembly
Carpentier et al. Mutations on the FG surface loop of human papillomavirus type 16 major capsid protein affect recognition by both type‐specific neutralizing antibodies and cross‐reactive antibodies
Renoux et al. Induction of antibody response against hepatitis E virus (HEV) with recombinant human papillomavirus pseudoviruses expressing truncated HEV capsid proteins in mice
EP0824359A1 (fr) Vaccin a base de peptides contre l'infection a virus du papillome
AU717647B2 (en) Chimeric papillomavirus-like particles
CA2201601C (fr) Particules de type papillomavirus chimeriques
AU683220C (en) Self-assembling recombinant papillomavirus capsid proteins
AU4447999A (en) Chimeric papillomavirus-like particles
HK1079239A (en) Self-assembling recombinant hpv16 papillomavirus capsid proteins
MXPA00003358A (en) Papilloma virus capsomere vaccine formulations and methods of use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 1999913478

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09647486

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1999913478

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999913478

Country of ref document: EP